Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Cyclobenzaprine hydrochloride - Tonix Pharmaceuticals

Next Previous
Drug Profile

Cyclobenzaprine hydrochloride - Tonix Pharmaceuticals

Alternative Names: Cyclobenzaprine HCL - Tonix Pharmaceuticals; cyclobenzaprine HCl sublingual tablet - Tonix Pharmaceuticals; KRL-102; TNX-102; TNX-102 SL; TNX-102 SL1; Tonmya; VLD-cyclobenzaprine

Latest Information Update: 31 Mar 2026

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Vela Pharmaceuticals
  • Developer Tonix Pharmaceuticals Holding Corp; Tonix Pharmaceuticals Inc
  • Class Amines; Anxiolytics; Behavioural disorder therapies; Dibenzocycloheptenes; Drug withdrawal therapies; Muscle relaxants; Non-opioid analgesics; Small molecules
  • Mechanism of Action Alpha 1 adrenergic receptor antagonists; Histamine H1 receptor antagonists; Muscarinic M1 receptor antagonists; Serotonin 5-HT2A receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed Fibromyalgia
  • Phase III Post-traumatic stress disorders
  • Phase II Acute traumatic stress disorders; Major depressive disorder; Post acute COVID 19 syndrome
  • Preclinical Agitation; Alcoholism

Most Recent Events

  • 18 Mar 2026 Phase-II clinical trials in Major depressive disorder (Treatment-naive, Monotherapy) in USA (Sublingual) prior to March 2026
  • 13 Mar 2026 Tonix Pharmaceuticals Holding Corp plans the phase II HORIZON trial for Major depressive disorders (Treatment-naive, Monotherapy) in USA (Sublingual), in mid-year 2026
  • 06 Mar 2026 Pharmacokinetics data from a phase I trial in healthy volunteers released by Tonix Pharmaceuticals

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top